EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Role of COVID-19 Vaccine in the Management of Gynecologic Oncology Lymphadenopathies

Laura Fernandez Sanahuja, Ester Miralpeix iD, Josep Maria Solé Sedeño, Marta Baucells, Berta Fabregó iD, Ana Sierra, Gemma Mancebo

International Journal of Environmental Research and Public Health · 2024

DOI: 10.3390/ijerph21081063 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Environmental Research and Public Health, 2024. Verfasst von Laura Fernandez Sanahuja und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Hospital del Mar, 08003 Barcelona, Spain. Hauptthemen laut MEDLINE: Genital Neoplasms, Female, COVID-19 Vaccines, Lymphadenopathy, COVID-19. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aimed to evaluate the incidence of lymphadenopathies after COVID-19 vaccination and their impact on the clinical management of gynecologic oncology patients.

Methods

A retrospective observational study was conducted involving patients who underwent abdominopelvic or thoracoabdominopelvic CT scans during diagnosis or follow-up. Patients were classified into a vaccinated group (Vac group) and a non-vaccinated group (NoVac group). The radiological appearance of lymphadenopathies was categorized as low or high risk of malignancy, and management strategies were recorded as standard management or additional assessment.

Results

75 patients were included, with 44 in the Vac group and 31 in the NoVac group. The incidence of lymphadenopathies was similar between the groups: 34.1% in the Vac group and 32.3% in the NoVac group (p = 0.868). High-risk lymphadenopathies were observed in 20.4% of the Vac group and 22.6% of the NoVac group, while low-risk lymphadenopathies were seen in 13.6% of the Vac group and 9.7% of the NoVac group (p = 0.691). Standard management was the most common approach, used in 80.0% of the Vac group and 100.0% of the NoVac group (p = 0.25).

Conclusions

COVID-19 vaccine does not increase the incidence of lymphadenopathies in imaging tests of gynecological cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genital Neoplasms, FemaleCOVID-19 VaccinesLymphadenopathyCOVID-19HumansFemaleRetrospective StudiesMiddle AgedAgedAdultSARS-CoV-2IncidenceTomography, X-Ray Computed

Stichwörter der Autor:innen

COVID-19gynecological cancerlymphadenopathiesvaccination

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Hospital del Mar, 08003 Barcelona, Spain.
  • School of Medicine, Universitat Pompeu Fabra, 08003 Barcelona, Spain.
  • Department of Radiology, Hospital del Mar, 08003 Barcelona, Spain.

ORCID-Profile: Ester Miralpeix, Berta Fabregó

Zitieren

APA

Fernandez Sanahuja, L., Miralpeix, E., Solé Sedeño, J. M., Baucells, M., Fabregó, B., Sierra, A., & Mancebo, G. (2024). Role of COVID-19 Vaccine in the Management of Gynecologic Oncology Lymphadenopathies. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph21081063

Vancouver

Fernandez Sanahuja L, Miralpeix E, Solé Sedeño JM, Baucells M, Fabregó B, Sierra A, et al. Role of COVID-19 Vaccine in the Management of Gynecologic Oncology Lymphadenopathies. International Journal of Environmental Research and Public Health. 2024. doi:10.3390/ijerph21081063

BibTeX
@article{FernandezSanahuja2024,
  author = {Fernandez Sanahuja, Laura and Miralpeix, Ester and Solé Sedeño, Josep Maria and Baucells, Marta and Fabregó, Berta and Sierra, Ana and Mancebo, Gemma},
  title = {Role of COVID-19 Vaccine in the Management of Gynecologic Oncology Lymphadenopathies},
  journal = {International Journal of Environmental Research and Public Health},
  year = {2024},
  doi = {10.3390/ijerph21081063}
}
Kostenlos starten →